HKEX: 1672
Interim Report 2026
Earlier from Ascletis Pharma
- Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque Psoriasis
- Ascletis Announces Initiation of Phase I Study in U.S. for Oral Amylin Receptor Peptide Agonist ASC36 for the Treatment of Obesity
- Ascletis Announces Inclusion in the Hong Kong Stock Connect List under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs
- Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management